a16z Capital Management, L.L.C.

Position in AKTS — Aktis Oncology, Inc.

CIK 1540358 MENLO PARK, CA

Position in AKTS

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$7,424,350

New position

Shares Held

415,000

first reported quarter

Ownership

0.751%

of shares outstanding

% of Portfolio

0.58%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2026

1 quarter on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

a16z Capital Management, L.L.C. holds $304,679,821 across 8 Biotechnology names. AKTS ranks #7 (2.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	RVMD	Revolution Medicines, Inc.	921,099	$89,576,877
2	NAUT	Nautilus Biotechnology, Inc.	17,653,917	$68,497,197
3	MAZE	Maze Therapeutics, Inc.	1,702,225	$50,811,416
4	ERAS	Erasca, Inc.	2,862,500	$46,315,250
5	DMRA	Damora Therapeutics, Inc.	1,236,157	$32,016,466
6	CAMP	Camp4 Therapeutics Corp	2,125,339	$9,372,744
7	AKTS	Aktis Oncology, Inc. This page	415,000	$7,424,350
8	DNA	Ginkgo Bioworks Holdings, Inc.	108,568	$665,521

1 filing row on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$7,424,350	415,000	—	Shares	Sole	2026-05-15
No filing history on record for this holder in this stock.